Sunifiram is a research ampakine that is becoming very popular amongst researchers. As an ampakine, it works to improve the ability of the AMPA glutamate receptors. Sunifiram works by stimulating the AMPA receptor currents therefore improving the glutamate signal. This is believed to be the main method of action however there are several other applications of this compound.
1) Sunifiram is good at improved decision making
2)A greater ability to convert short-term memory into long-term memory
3)Improved motor skills via increased control over muscle contraction
4) Sunifiram can enhanced memory and retention of learned information and activities
Sunifiram (developmental code name DM-235) is an experimental drug which has antiamnesic effects in animal studies and with significantly higher potency than piracetam. Sunifiram is a molecular simplification of unifiram (DM-232). Another analogue is sapunifiram (MN-19). As of 2016, sunifiram had not been subjected to toxicology testing, nor to any human clinical trials, and is not approved for use anywhere in the world. The mechanism of action of sunifiram is unknown. Sunifiram, as well as unifiram, were assayed at a wide panel of sites, including the most important receptors, ion channels, and transporters, but showed no affinity for any of the sites. They specifically did not bind to the glutamate, GABA, serotonin, dopamine, adrenergic, histamine, acetylcholine, or opioid receptors at concentrations of up to 1 μM. In addition, the drugs were tested on recombinant AMPA receptors and showed no potentiation of the receptors, indicating that they do not act as AMPA receptor positive allosteric modulators.